Funded Biotechnology Startups in Los Angeles
Among the 30 most recent Los Angeles biotechnology rounds shown (sorted by round date descending), one disclosed amount stands out: ACELYRIN’s $300M Series…
Among the 30 most recent Los Angeles biotechnology rounds shown (sorted by round date descending), one disclosed amount stands out: ACELYRIN’s $300M Series C on 2022-09-13. The next-largest disclosed rounds are $200M (Saku Biosciences, 2026-05-18) and $150M (Immix Biopharma, 2026-05-21; Capricor Therapeutics, 2025-12-05), which keep most disclosed values clustered far below that $300M peak.
Timing also clusters: the list spans 2020-09-23 (Force Impact Technologies Inc.) through 2026-05-27 (Ember LifeSciences). In the most recent 90 days, multiple entries land in May 2026 (Ember LifeSciences, 2026-05-27; Immix Biopharma, 2026-05-21; Saku Biosciences, 2026-05-18), and several additional biotech rounds appear again in December 2025 (Capricor Therapeutics on 2025-12-05 at $150M, plus other entries on 2025-12-03 and 2025-12-15).
Most recent rounds
30 shownRelated listings
Frequently asked
What’s the largest disclosed round here, and how does it compare to the rest of the disclosed amounts?
ACELYRIN’s $300M Series C on 2022-09-13 is the clear outlier. The largest amounts below it are $200M (Saku Biosciences, 2026-05-18) and $150M (Immix Biopharma, 2026-05-21; Capricor Therapeutics, 2025-12-05), keeping the remainder of disclosed rounds generally in lower ranges.
Which stage labeling pattern stands out: 'Series Unknown' and 'undisclosed' amounts?
Stage information is frequently opaque: five companies are marked 'Series Unknown' (e.g., Kairos Pharma on 2026-01-12 for $75M; Capricor Therapeutics on 2025-12-05 for $150M). Separately, three rounds have undisclosed amounts: Ember LifeSciences (2026-05-27), PopID (2025-12-03), and 9 Dots (2024-07-25).
Are there dense date clusters among the most recent entries?
Yes. The May 2026 window includes Ember LifeSciences (2026-05-27, undisclosed), Immix Biopharma (2026-05-21, $150M), and Saku Biosciences (2026-05-18, $200K), followed by additional December 2025 activity such as Capricor Therapeutics (2025-12-05, $150M), PopID (2025-12-03, undisclosed), and NeuroSigma (2025-12-15, $1M).
Which stages appear most often among the dated rounds with explicit amounts?
'Seed' rounds recur multiple times with disclosed figures: Rarity PBC ($5M on 2025-10-30), Sequencing.com ($5M on 2022-11-09), and Partillion Bioscience ($5M on 2023-09-26). 'Series A' also shows up repeatedly with both $6M (Evergreen, 2026-02-04) and $10M (Dyania Health, 2024-10-24), alongside Bionaut Labs at $20M (2021-03-03).
Is there a small disclosed-amount outlier relative to the rest of the disclosed rounds?
PathoGene’s $500K Seed round on 2021-07-14 is the smallest disclosed amount in the list. Several other low disclosed values cluster above it (e.g., Azora Therapeutics at $580K on 2023-08-08; MyoGene Bio at $400K on 2025-11-04), but $500K is the lowest disclosed figure shown.
What geographic pattern appears in the city field across these 30 rows?
All entries are listed as Los Angeles, California, United States with no alternate cities shown. That means there is no intra-state city splitting in this dataset, and the comparison is strictly within the Los Angeles geography for biotechnology funding rounds.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.